Brandywine Global Investment Management LLC Acquires New Position in Genmab A/S (NASDAQ:GMAB)

Brandywine Global Investment Management LLC acquired a new position in shares of Genmab A/S (NASDAQ:GMAB) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,619,764 shares of the company’s stock, valued at approximately $33,804,000.

Other hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock valued at $186,000 after buying an additional 827 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC grew its holdings in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after acquiring an additional 950 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after buying an additional 1,051 shares in the last quarter. Finally, Grandfield & Dodd LLC lifted its stake in shares of Genmab A/S by 4.2% in the 4th quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company’s stock valued at $704,000 after purchasing an additional 1,370 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on GMAB. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research report on Thursday, February 13th. Truist Financial lowered their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $41.33.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $19.90 on Friday. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $30.50. The company has a market capitalization of $13.17 billion, a P/E ratio of 11.44, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The company has a 50-day simple moving average of $20.89 and a 200 day simple moving average of $21.88.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, equities analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.